GlassScriptPhysician profile
Amy W Rains
NPI 1801206859
$55,280.62
in general payments reported to CMS, 2019-2025
53 companies · $6,499 in 2025
The $6,499 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,421 · 2022: $18K · 2023: $14K · 2024: $10K · 2025: $6,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $9,251 · Travel and Lodging: $1,796 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,765.00 |
| Food and Beverage | $9,251.08 |
| Travel and Lodging | $1,795.90 |
| Education | $182.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41,793.63 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $3,774.76 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Boston Scientific Corporation | $1,950.82 | 2023-2024 | Vercise, Watchman Access System |
| Acadia Pharmaceuticals INC | $1,392.67 | 2021-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $930.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $755.56 | 2022 | |
| Pfizer INC. | $676.76 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $597.04 | 2021-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $423.06 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Kyowa Kirin, INC. | $309.79 | 2021-2025 | Nourianz |
| Supernus Pharmaceuticals, INC. | $245.67 | 2021-2023 | |
| Lundbeck LLC | $224.58 | 2023-2025 | Vyepti |
| Mdd US Operations, LLC | $221.89 | 2022-2025 | Gocovri, Gocovri, Qelbree |
| Biogen, INC. | $218.15 | 2021-2024 | Skyclarys, Spinraza, Qalsody |
| Ucb, INC. | $172.42 | 2021-2025 | Rystiggo |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Rains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.